Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption ...
The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...
India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...
Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...
A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...
Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings. Jeff Auletta, MD, senior vice president of health equity at the National Marrow Donor Program and ...
And we continue to see momentum for the product. We aspire to become a global leader in this field with Bemiparin and Enoxaparin biosimilar. In this context, we’re investing not only increase ...
Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United ...
Results from the phase 3 trial showed biosimilar denosumab was comparable to the reference product with regard to efficacy, safety, immunogenicity, PK, and pharmacodynamics (PD) in patients with ...
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar. … ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...
The launch marks a significant move, as YESINTEK is among the first biosimilar alternatives to Stelara (ustekinumab) to enter the US market. YESINTEK is approved for Crohn’s disease, ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback